Ribociclib Succinate

CAS 1374639-75-4

General Information

Ribociclib succinate is a type of cyclin-dependent kinase inhibitor. It was developed by Novartis and Astex Pharmaceuticals. It is used to treat hormone-receptor positive (HR+), HER2 negative (HER2-) breast cancer that is advanced or has spread to other parts of the body.

Ribociclib succinate is used with fulvestrant in postmenopausal women who have not been treated with hormone therapy or whose breast cancer got worse during treatment with hormone therapy. It is also being studied in the treatment of other types of cancer. Ribociclib succinate blocks certain proteins, which may help keep cancer cells from growing.

Talk to us now about the new US DMF available for our novel, crystalline form B of Ribociclib succinate.

In addition to the form B which has a high chemical purity, we also offer an anhydrous crystalline form and can scale it up as needed. Get in touch! Both forms are offered for development purposes only.


About the API

Systematic name 7-Cyclopentyl-N,N-dimethyl-2-((5-(piperazin-1-yl)pyridin-2-yl)amino)-7H-pyrrolo[2,3-d]pyrimidine-6-carboxamide succinate
Trade name(s) Kisqali
Molecular Formula C27H36N8O5
Therapeutic category Oncology
Available formulations Oral Solid
Regulations US DMF Flag US DMF